PregnancyNCT02550444
Intrathecal Clonidine in Cesarean Section May Lead to Worse Blood Gas Results in the Newborns
A study testing Intrathecal Clonidine and Intravenous Clonidine in people with Pregnancy, run by University of Sao Paulo General Hospital.
Trial summary
The purpose of this study is to evaluate effects of intravenous clonidine in acute and chronic post-cesarean pain, possible adverse effects over mother-newborn pair, in comparison to intrathecal adjuvant clonidine and placebo. Read more about this study
- Who is it for?
- Ages 18 years and older, women onlyHealthy volunteers can take part
- Conditions the study is for
- Pregnancy
- What is being tested?
- Intrathecal Clonidine and Intravenous Clonidine
- Type of treatment
- Injection or infusion
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 64 participants
- Where
- No sites listed yet
- Study dates
- Apr 2015to Jun 2016
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- Women only
- Healthy volunteers accepted
- Adult, Older adult
Who may be able to join
- term pregnancy;
- elective cesarean (no labor).
Who cannot join
- multiple pregnancy;
- moderate or several systemic disease, categorized as American Society of Anesthesiology physical status (ASA) higher or equal to 3;
- contraindications for spinal anesthesia;
- contraindications for the drugs involved in the study;
- uncontrolled high blood pressure or diabetes mellitus in need of insulin therapy;
- intravenous psychotropic drugs users;
- previously known malformation on the fetus;
- patients with previous history of chronic pain.
About this study
Official title: Comparison Between Intravenous and Intrathecal Clonidine in Post-cesarean Analgesia
The purpose of this study is to evaluate effects of intravenous clonidine in acute and chronic post-cesarean pain, possible adverse effects over mother-newborn pair, in comparison to intrathecal adjuvant clonidine and placebo.
Read the detailed description
METHODS Patients The research was submitted and approved by the Clinics Hospital of University of São Paulo Ethics in Research Board (CAAE 05847312.8.0000.0068, Nº 940.941). Patients authorized their participation and the proposed interventions and data collection, through signature of Free Consent Term.
Inclusion criteria were women aged 18 years or older, in term pregnancy, who underwent elective cesarean (no labor). Exclusion criteria was the following: multiple pregnancy; moderate or several systemic disease, categorized as American Society of Anesthesiology physical status (ASA) higher or equal to 3; contraindications for spinal anesthesia; contraindications for the drugs involved in the study; uncontrolled high blood pressure or diabetes mellitus in need of insulin therapy; intravenous psychotropic drugs users; previously known malformation on the fetus; and patients with previous history of chronic pain.
Patients anesthetic management All volunteers were managed according to the hospital protocol for cesarean delivery, and the one difference between groups was the clonidine or placebo given intrathecally or intravenously. Multiparameter non-invasive monitoring was used. The patients received a intravenous 10ml/kg Ringer Lactate bolus during realization of spinal anesthesia with heavy Bupivacaine 0,5% (15mg), morphine 0,02 (80mcg) and fentanyl (10mcg). Blood pressure was measured non-invasively during intra-operative period, each 1 minute until the baby was born, and each 3 minutes after the delivery. Low blood pressure was treated with Metaraminol 0,2mg intravenous bolus and/or Ephedrine 5mg intravenous bolus. Bradycardia was defined as heart rate inferior to 45 beats per minute, and treated with Atropine 0,5mg intravenous bolus. Intra-operative rescue analgesia was provided, if necessary, according to the patients needs or if the assistant anesthetist felt that it was necessary, with Fentanyl intravenous bolus, until a maximum dose of 100mcg. Before the skin incision, the patient received cefazolin 2g IV. After cord clamp, patients received Oxytocin 5 international units diluted in Ringer Lactate 250ml, ketoprofen 100mg IV, Dipyrone 2g IV, Omeprazole 40mg IV, Ondansetron 8mg IV. After procedure, the women were driven to Post Anesthetic Care Unit (PACU). There, if they felt pain, they could receive morphine 2mg IV, each 5 minutes, according to the patients needs. Post-operative pain control in the ward was standardized on the following protocol: ketoprofen 100mg IV 12/12h, Dipyrone 2g IV 6/6h; Tramadol IV 100mg maximum 8/8h, if uncontrolled pain. If pain persists, morphine subcutaneously, 5mg could be administered by nurse, 4/4h. Nauseas were treated with Dimenhydrinate 50mg IV 6/6h and Metoclopramide 10mg IV 8/8h, and itch was attenuated with Diphenhydramine 25mg IV, in case of such symptoms.
A neonatology team was present in every delivery and was responsible for the first evaluation of the newborn, including Apgar score and resuscitation.
Groups and interventions The included patients were randomly divided into one of three groups. The professional who administered the drugs was external to de research group, and did it unblinded. The researcher who did the assessments of the variables was blind for what intervention had been made. In control group, patients received placebo intravenously and intrathecally. In the intrathecal clonidine group, patients received 75 mcg of spinal clonidine, and intravenous placebo. In the intravenous clonidine group, patients received 75 mcg of intravenous clonidine, and spinal placebo. The solutions volumes were the same in all three groups, by 0,9% saline fluid addition to intrathecal and intravenous infusions.
Outcomes Data including age, height, weight, body mass index (BMI), number of pregnancies, number of deliveries, associated morbidities, American Society of Anesthesiology (ASA) physical status classification, reason to cesarean, length of anesthesia, amount of fluids needed, basal blood pressure, minimum and maximum values, heart rate variation, vasopressor and chronotropic drugs need, anesthesia complications, adverse effects (nauseas, vomits, itch and shivering) and analgesic complementation intra-operative needs were registered. Systolic, diastolic and mean hypotension was considered when values decreased more than 20% of basal values. During the stay at PACU, motor block duration (time from beginning of the anesthesia until the patient be able to do 90º flexion movement of tights over hips and 90º flexion movement of legs over tights, on both inferior limbs, simultaneously and sustained for 5 seconds or more), pain and adverse effects were evaluated. Patients were assessed by researchers in 6, 12, 24 and 48 hours after spinal anesthesia induction. Post-operative pain was measured using a number verbal scale (NVS), from 0 to 10 (0 is equivalent to no pain at all and 10 means the worst pain ever). Patients informed their pain in rest and after been asked to change from the lying position to the sitting position. Treatment satisfaction was evaluated using a 0-10 scale, in which 0 meant unsatisfied and 10 full satisfaction. Patients were asked by research team to quantify the intensity of itch, nausea, vomit and dizziness in a four points scale (0=none, 1=mild, 2=moderate, 3=severe). Sedation was measured by the Richmond Agitation and Sedation Scale.
After 3 months, the women were evaluated trough a individual telephone call by a member of study team, when they were asked if they had any pain or abnormal sensation (burning, itch and numbness) at the section site; if they had any functional limitation due to pain; if they needed any drug for section site pain in last week; if they were nursing; and if the not-nursing reason was due to pain.
Newborn data included gestational age, weight after born, Apgar score at first, fifty and tenth minutes, umbilical artery blood gas analysis, and Neonatal Intensive Care Unit (ICU) admission need.
- Conditions
- Pregnancy
- Being tested
- Intrathecal Clonidine, Intravenous Clonidine, Placebo
- Keywords
- Clonidine, Anesthesia, Obstetrical
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Intrathecal ClonidineDrug
Also called Clonidine
Intrathecal Adjuvant Clonidine 75 mcg; Intravenous Placebo (Saline 0,9%); Intrathecal heavy Bupivacaine 0,5% (15mg), morphine 0,02 (80mcg) and fentanyl (10mcg).
Intravenous ClonidineDrug
Also called Clonidine
Intravenous Clonidine 75 mcg; Intrathecal Placebo (Saline 0,9%); Intrathecal heavy Bupivacaine 0,5% (15mg), morphine 0,02 (80mcg) and fentanyl (10mcg).
PlaceboDrug
Also called Saline
Intravenous and intrathecal Placebo (Saline 0,9%); Intrathecal heavy Bupivacaine 0,5% (15mg), morphine 0,02 (80mcg) and fentanyl (10mcg).
| Study group | Role | What they receive |
|---|---|---|
| Control | Placebo comparator | Intravenous and intrathecal Placebo (Saline 0,9%); Intrathecal heavy Bupivacaine 0,5% (15mg), morphine 0,02 (80mcg) and fentanyl (10mcg). Receives: Drug: Placebo |
| Intrathecal Clonidine | Experimental | Intrathecal Adjuvant Clonidine 75 mcg; Intravenous Placebo (Saline 0,9%); Intrathecal heavy Bupivacaine 0,5% (15mg), morphine 0,02 (80mcg) and fentanyl (10mcg). Receives: Drug: Intrathecal Clonidine |
| Intravenous Clonidine | Experimental | Intravenous Clonidine 75 mcg; Intrathecal Placebo (Saline 0,9%); Intrathecal heavy Bupivacaine 0,5% (15mg), morphine 0,02 (80mcg) and fentanyl (10mcg). Receives: Drug: Intravenous Clonidine |
What is being measured
The primary outcome is the main question the study is designed to answer.
Umbilical Artery Blood Gas Analysis - pH
pH
Measured: Right after born
Umbilical Artery Serum Lactate
Lactate
Measured: Right after born
Newborn Apgar Score
Score can vary from 0 to 10.
Measured: First, Fifth and Tenth minutes after born
Secondary outcomes (4)
Maternal heart rate
Heart rate during anesthesia
Measured: Intraoperatively
Maternal blood pressure variation
Maximum and minimum blood pressure values
Measured: Intraoperatively
Numerical verbal scale for pain
Score varies from 0 to 10
Measured: 6, 12, 24 and 48 hours after cesarean section
Maternal sedation
Richmond Agitation and Sedation Scale (varies from -5 to +4)
Measured: Intraoperatively
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted15 Sep 2015 (estimated)
- Study startApr 2015
- Primary completionMay 2015
- Study completionJun 2016
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (4)Papers the sponsor has linked to this study.
- Other trials for PregnancyStudies of the same condition, open and under way.
- More trials run by University of Sao Paulo General HospitalThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Triple blind
- Who is masked
- Participant, Care provider, Outcomes assessor
- Enrolment
- 64 participants (actual)
Sponsor and investigators
- Lead sponsor
- University of Sao Paulo General Hospital
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
- Investigators
- Hermann S Fernandes, MD, Principal investigator, Clinics Hospital of University of São Paulo Medical School
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT02550444
- Sponsor's protocol ID
- CAAE 05847312.8.0000.0068
- Status last verified
- Sep 2015
- First submitted
- 4 Sep 2015
- Last updated
- 1 Nov 2017
- Results posted
- No
- Data monitoring committee
- No
Publications
Mayor S. 23% of babies in England are delivered by caesarean section. BMJ. 2005 Apr 9;330(7495):806. doi: 10.1136/bmj.330.7495.806-a. No abstract available.
PubMed 15817536Eisenach JC, De Kock M, Klimscha W. alpha(2)-adrenergic agonists for regional anesthesia. A clinical review of clonidine (1984-1995). Anesthesiology. 1996 Sep;85(3):655-74. doi: 10.1097/00000542-199609000-00026. No abstract available.
PubMed 8853097Filos KS, Goudas LC, Patroni O, Polyzou V. Intrathecal clonidine as a sole analgesic for pain relief after cesarean section. Anesthesiology. 1992 Aug;77(2):267-74. doi: 10.1097/00000542-199208000-00008.
PubMed 1642346Fernandes HS, Bliacheriene F, Vago TM, Corregliano GT, Torres ML, Francisco RP, Ashmawi HA. Clonidine Effect on Pain After Cesarean Delivery: A Randomized Controlled Trial of Different Routes of Administration. Anesth Analg. 2018 Jul;127(1):165-170. doi: 10.1213/ANE.0000000000003319.
PubMed 29596102
Study at a glance
From the registry record, last updated by the sponsor on 1 Nov 2017. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Comparison Between Intravenous and Intrathecal Clonidine in Post-cesarean Analgesia
- ClinicalTrials.gov ID
- NCT02550444
- Acronym / sponsor ID
- CAAE 05847312.8.0000.0068
- Conditions
- Pregnancy
- Keywords
- Clonidine, Anesthesia, Obstetrical
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 64 participants (actual)
- Lead sponsor
- University of Sao Paulo General HospitalUniversity, hospital or other
- Study start
- Apr 2015
- Primary completion
- May 2015 (actual)
- Study completion
- Jun 2016 (actual)
- First posted
- 15 Sep 2015 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The purpose of this study is to evaluate effects of intravenous clonidine in acute and chronic post-cesarean pain, possible adverse effects over mother-newborn pair, in comparison to intrathecal adjuvant clonidine and placebo.
Detailed description
METHODS Patients The research was submitted and approved by the Clinics Hospital of University of São Paulo Ethics in Research Board (CAAE 05847312.8.0000.0068, Nº 940.941). Patients authorized their participation and the proposed interventions and data collection, through signature of Free Consent Term.
Inclusion criteria were women aged 18 years or older, in term pregnancy, who underwent elective cesarean (no labor). Exclusion criteria was the following: multiple pregnancy; moderate or several systemic disease, categorized as American Society of Anesthesiology physical status (ASA) higher or equal to 3; contraindications for spinal anesthesia; contraindications for the drugs involved in the study; uncontrolled high blood pressure or diabetes mellitus in need of insulin therapy; intravenous psychotropic drugs users; previously known malformation on the fetus; and patients with previous history of chronic pain.
Patients anesthetic management All volunteers were managed according to the hospital protocol for cesarean delivery, and the one difference between groups was the clonidine or placebo given intrathecally or intravenously. Multiparameter non-invasive monitoring was used. The patients received a intravenous 10ml/kg Ringer Lactate bolus during realization of spinal anesthesia with heavy Bupivacaine 0,5% (15mg), morphine 0,02 (80mcg) and fentanyl (10mcg). Blood pressure was measured non-invasively during intra-operative period, each 1 minute until the baby was born, and each 3 minutes after the delivery. Low blood pressure was treated with Metaraminol 0,2mg intravenous bolus and/or Ephedrine 5mg intravenous bolus. Bradycardia was defined as heart rate inferior to 45 beats per minute, and treated with Atropine 0,5mg intravenous bolus. Intra-operative rescue analgesia was provided, if necessary, according to the patients needs or if the assistant anesthetist felt that it was necessary, with Fentanyl intravenous bolus, until a maximum dose of 100mcg. Before the skin incision, the patient received cefazolin 2g IV. After cord clamp, patients received Oxytocin 5 international units diluted in Ringer Lactate 250ml, ketoprofen 100mg IV, Dipyrone 2g IV, Omeprazole 40mg IV, Ondansetron 8mg IV. After procedure, the women were driven to Post Anesthetic Care Unit (PACU). There, if they felt pain, they could receive morphine 2mg IV, each 5 minutes, according to the patients needs. Post-operative pain control in the ward was standardized on the following protocol: ketoprofen 100mg IV 12/12h, Dipyrone 2g IV 6/6h; Tramadol IV 100mg maximum 8/8h, if uncontrolled pain. If pain persists, morphine subcutaneously, 5mg could be administered by nurse, 4/4h. Nauseas were treated with Dimenhydrinate 50mg IV 6/6h and Metoclopramide 10mg IV 8/8h, and itch was attenuated with Diphenhydramine 25mg IV, in case of such symptoms.
A neonatology team was present in every delivery and was responsible for the first evaluation of the newborn, including Apgar score and resuscitation.
Groups and interventions The included patients were randomly divided into one of three groups. The professional who administered the drugs was external to de research group, and did it unblinded. The researcher who did the assessments of the variables was blind for what intervention had been made. In control group, patients received placebo intravenously and intrathecally. In the intrathecal clonidine group, patients received 75 mcg of spinal clonidine, and intravenous placebo. In the intravenous clonidine group, patients received 75 mcg of intravenous clonidine, and spinal placebo. The solutions volumes were the same in all three groups, by 0,9% saline fluid addition to intrathecal and intravenous infusions.
Outcomes Data including age, height, weight, body mass index (BMI), number of pregnancies, number of deliveries, associated morbidities, American Society of Anesthesiology (ASA) physical status classification, reason to cesarean, length of anesthesia, amount of fluids needed, basal blood pressure, minimum and maximum values, heart rate variation, vasopressor and chronotropic drugs need, anesthesia complications, adverse effects (nauseas, vomits, itch and shivering) and analgesic complementation intra-operative needs were registered. Systolic, diastolic and mean hypotension was considered when values decreased more than 20% of basal values. During the stay at PACU, motor block duration (time from beginning of the anesthesia until the patient be able to do 90º flexion movement of tights over hips and 90º flexion movement of legs over tights, on both inferior limbs, simultaneously and sustained for 5 seconds or more), pain and adverse effects were evaluated. Patients were assessed by researchers in 6, 12, 24 and 48 hours after spinal anesthesia induction. Post-operative pain was measured using a number verbal scale (NVS), from 0 to 10 (0 is equivalent to no pain at all and 10 means the worst pain ever). Patients informed their pain in rest and after been asked to change from the lying position to the sitting position. Treatment satisfaction was evaluated using a 0-10 scale, in which 0 meant unsatisfied and 10 full satisfaction. Patients were asked by research team to quantify the intensity of itch, nausea, vomit and dizziness in a four points scale (0=none, 1=mild, 2=moderate, 3=severe). Sedation was measured by the Richmond Agitation and Sedation Scale.
After 3 months, the women were evaluated trough a individual telephone call by a member of study team, when they were asked if they had any pain or abnormal sensation (burning, itch and numbness) at the section site; if they had any functional limitation due to pain; if they needed any drug for section site pain in last week; if they were nursing; and if the not-nursing reason was due to pain.
Newborn data included gestational age, weight after born, Apgar score at first, fifty and tenth minutes, umbilical artery blood gas analysis, and Neonatal Intensive Care Unit (ICU) admission need.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Triple blind (participant, care provider, outcomes assessor)
- Number of arms
- 3
| Arm | Type | Receives |
|---|---|---|
| Control | Placebo comparator | Drug: PlaceboIntravenous and intrathecal Placebo (Saline 0,9%); Intrathecal heavy Bupivacaine 0,5% (15mg), morphine 0,02 (80mcg) and fentanyl (10mcg). |
| Intrathecal Clonidine | Experimental | Drug: Intrathecal ClonidineIntrathecal Adjuvant Clonidine 75 mcg; Intravenous Placebo (Saline 0,9%); Intrathecal heavy Bupivacaine 0,5% (15mg), morphine 0,02 (80mcg) and fentanyl (10mcg). |
| Intravenous Clonidine | Experimental | Drug: Intravenous ClonidineIntravenous Clonidine 75 mcg; Intrathecal Placebo (Saline 0,9%); Intrathecal heavy Bupivacaine 0,5% (15mg), morphine 0,02 (80mcg) and fentanyl (10mcg). |
Who may qualify
- Ages
- 18 years and older
- Sex
- Female only
- Healthy volunteers
- Accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (2 listed)
- term pregnancy;
- elective cesarean (no labor).
Key exclusion criteria (8 listed)
- multiple pregnancy;
- moderate or several systemic disease, categorized as American Society of Anesthesiology physical status (ASA) higher or equal to 3;
- contraindications for spinal anesthesia;
- contraindications for the drugs involved in the study;
- uncontrolled high blood pressure or diabetes mellitus in need of insulin therapy;
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Intrathecal ClonidineAlso: ClonidineIntrathecal Adjuvant Clonidine 75 mcg; Intravenous Placebo (Saline 0,9%); Intrathecal heavy Bupivacaine 0,5% (15mg), morphine 0,02 (80mcg) and fentanyl (10mcg). | Drug | Intrathecal Clonidine |
| Intravenous ClonidineAlso: ClonidineIntravenous Clonidine 75 mcg; Intrathecal Placebo (Saline 0,9%); Intrathecal heavy Bupivacaine 0,5% (15mg), morphine 0,02 (80mcg) and fentanyl (10mcg). | Drug | Intravenous Clonidine |
| PlaceboAlso: SalineIntravenous and intrathecal Placebo (Saline 0,9%); Intrathecal heavy Bupivacaine 0,5% (15mg), morphine 0,02 (80mcg) and fentanyl (10mcg). | Drug | Control |
Primary outcome
Umbilical Artery Blood Gas Analysis - pH
Time frame: Right after born
pH
Umbilical Artery Serum Lactate
Time frame: Right after born
Lactate
Newborn Apgar Score
Time frame: First, Fifth and Tenth minutes after born
Score can vary from 0 to 10.
4 secondary outcomes
Maternal heart rate
Time frame: Intraoperatively
Maternal blood pressure variation
Time frame: Intraoperatively
Numerical verbal scale for pain
Time frame: 6, 12, 24 and 48 hours after cesarean section
Maternal sedation
Time frame: Intraoperatively
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 1 Nov 2017.
- Background: PubMed 15817536Mayor S. 23% of babies in England are delivered by caesarean section. BMJ. 2005 Apr 9;330(7495):806. doi: 10.1136/bmj.330.7495.806-a. No abstract available.
- Background: PubMed 8853097Eisenach JC, De Kock M, Klimscha W. alpha(2)-adrenergic agonists for regional anesthesia. A clinical review of clonidine (1984-1995). Anesthesiology. 1996 Sep;85(3):655-74. doi: 10.1097/00000542-199609000-00026. No abstract available.
- Background: PubMed 1642346Filos KS, Goudas LC, Patroni O, Polyzou V. Intrathecal clonidine as a sole analgesic for pain relief after cesarean section. Anesthesiology. 1992 Aug;77(2):267-74. doi: 10.1097/00000542-199208000-00008.
- Derived from this study: PubMed 29596102Fernandes HS, Bliacheriene F, Vago TM, Corregliano GT, Torres ML, Francisco RP, Ashmawi HA. Clonidine Effect on Pain After Cesarean Delivery: A Randomized Controlled Trial of Different Routes of Administration. Anesth Analg. 2018 Jul;127(1):165-170. doi: 10.1213/ANE.0000000000003319.
Related trials for Pregnancy
Recruiting
Methylation Profiling in Self-Samples for Identification of (Epi)Genetic Biomarkers for Gynecological Cancers
Gynaecological Cancers, Ovarian Cancer
RecruitingPhase 1/2
Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)
Solid Tumor, Non-Small Cell Lung Cancer
RecruitingObservational study
Population Pharmacokinetics of Temocillin in Acute Enterobacterial Pyelonephritis in Children
Pyelonephritis
Active, not recruitingPhase 3
A Study of Belzutifan (MK-6482) in Combination With Lenvatinib Versus Cabozantinib for Treatment of Renal Cell Carcinoma (MK-6482-011)
Carcinoma, Renal Cell
Recruiting
Safety and Performance of UCon Patch Electrode
Urinary Incontinence, Urinary Incontinence, Urge
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Hermann S Fernandes, MD principal investigator
Clinics Hospital of University of São Paulo Medical School
Questions about this trial
What is this clinical trial studying?
A study testing Intrathecal Clonidine and Intravenous Clonidine in people with Pregnancy, run by University of Sao Paulo General Hospital.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 2 inclusion and 8 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 1 Nov 2017. Status can change between updates, so confirm with the study contact before making plans.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Umbilical Artery Blood Gas Analysis - pH (time frame: Right after born). The study lists 3 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT02550444, which also lists 4 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 1 Nov 2017.